- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Cancer1000
- Pathology961
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Cancer1000
- Pathology961
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- EGFR positive
- EGFR negative
- PD-L1 negative
- ER negative
- PR negative
- ALK negative
- KRAS positive
- BRAF positive
- CD20 positive
- BRCA1 positive
- ALK positive
- BRCA2 positive
- BRAF negative
- IDH positive
- p16 positive
- ROS1 negative
- CD19 positive
- HLA positive
- HR positive
- MET positive
- MYC positive
- HLA-A positive
- PIK3CA positive
- RET positive
- ROS1 positive
- TP53 positive
- dMMR positive
- IDH negative
- p16 negative
- BCL2 positive
- CD5 positive
- MET negative
- MSI-H positive
- NF1 positive
- ANA positive
- BCL6 positive
- HPV positive
- KRAS negative
- NRAS positive
- NTRK positive
- PALB2 positive
- TP53 negative
- anti-dsDNA positive
- HBsAg positive
- HPV negative
- MSS positive
- RAS positive
- RET negative
- BCR-ABL1 positive
- BRCA1 negative
- CCND1 positive
- CFTR positive
- Ex19del positive
- L858R positive
- ctDNA positive
- pMMR positive
- ABCA4 positive
- BRCA positive
- BRCA2 negative
- FGFR2 positive
- FLT3 positive
- HLA negative
- HLA-A negative
- NTRK negative
- PTEN positive
- RAS negative
- RB1 positive
- TTR positive
- anti-Sm positive
- CD123 positive
- CD19 negative
- CD20 negative
- CD4 positive
- CLDN18.2 positive
- COL7A1 positive
- DMD positive
- MDM2 positive
- MGMT negative
- MMR negative
- Philadelphia chromosome negative
- RB1 negative
- T790M positive
- TROP2 negative
- TROP2 positive
- 1p negative
- AKT negative
- APP positive
- C5 positive
- CD23 positive
- CD30 positive
- DLL3 positive
- EBV positive
- ER/PR positive
- FLT3 negative
- FMR1 positive
- HBV DNA negative
- HR negative
- HRAS positive
- MGMT positive
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- MSI-H negative
- NRAS negative
- PMS2 positive
- PSEN1 positive
- PSEN2 positive
- PTCH1 positive
- Philadelphia chromosome positive
- PiZZ positive
- RF positive
- RHO positive
- SMARCA4 positive
- dMMR negative
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- AKT positive
- ALPL positive
- ALT positive
- APOL1 positive
- ARID1A positive
- ATM positive
- Anti-PLA2R positive
- Aβ1-42 positive
- B7-H3 positive
- CAG repeat in HTT positive
- CD1a positive
- CD2 positive
- CD22 negative
- CD3 positive
- CD34 positive
- CD7 positive
- CD8 positive
- CD99 positive
- CDK4 positive
- CEACAM5 positive
- COL1A1 positive
- COL1A2 positive
- EBV DNA positive
- EPCAM positive
- ER or PR positive
- FGFR3 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GPC3 positive
- GRN positive
- HBB positive
- HBcAb negative
- HBcAb positive
- HBsAg negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- KIT positive
- Ki-67 positive
- L861Q positive
- MSS negative
- MUC1 positive
- MYC negative
- NF2 positive
- NPM1 positive
- NTRK1 positive
- NY-ESO-1 positive
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PTEN negative
- Ph positive
- RAF positive
- S768I positive
- SMARCB1 negative
- SMN1 positive
- SPINK5 positive
- TET2 positive
- TTR negative
- TdT positive
- UBA1 positive
- UGT1A1 positive
- anti-AChR positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Anthracycline
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6903 trials
1
2
3
…50